Eleven Biotherapeutics

OphthalmicsUSA

Eleven Biotherapeutics

Eleven Biotherapeutics (NASDAQ: EBIO ) is a US-based clinical-stage biopharmaceutical company that applies its proprietary protein engineering platform, AMP-Rx, to the discovery and development of protein therapeutics to treat diseases of the eye.

Eleven Biotherapeutics (NASDAQ: EBIO ) is a US-based clinical-stage biopharmaceutical company that applies its proprietary protein engineering platform, AMP-Rx, to the discovery and development of protein therapeutics to treat diseases of the eye.

Eleven’s lead drug candidate, EBI-005, is the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration. Clinical data on EBI-005 has demonstrated improvements in signs and symptoms of dry eye disease (DED), including reduction in ocular pain and artificial tear use.

In addition, preclinical data on Eleven’s EBI-029, an IL-6 (Interleukin-6) inhibitor optimized for localized ocular administration in diabetic macular edema (DME), has demonstrated that EBI-029 potently inhibits IL-6 signaling in vitro. IL-6 is a cytokine that has previously been shown to be upregulated in DME, contributing to the angiogenic and inflammatory components of the disease and correlating with disease severity. By inhibiting IL-6, EBI-029 could offer an alternative to current standard of care, including anti-VEGF therapies.


Latest Articles

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top